Cambridge, MA, and Basel-based CRISPR Therapeutics has bolstered its board of directors. Yumanity Therapeutics CEO and former Onyx Pharmaceuticals CEO Tony Coles—who was already on CRISPR’s board—was named chairman, replacing Versant Ventures managing director Brad Bolzon. Pablo Cagnoni, another Onyx veteran and currently the president and CEO of South San Francisco, CA, startup Tizona Therapeutics, also joined CRISPR’s board.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler